Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Due to system maintenance, login and edit functionaility is currently unavailable

Clinical safety of the selective PKC-beta inhibitor, ruboxistaurin.

Clinical safety of the selective PKC-beta inhibitor, ruboxistaurin. Expert Opin Drug Saf. 2006 Nov; 5(6):835-45.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.